ASX Announcement | 16 March 2021
Noxopharm Limited (ASX:NOX)

ASX Small-Mid Cap Conference Corporate Presentation

Sydney 16 March 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces that CEO and Founder, Dr Graham Kelly, has been invited to present at the virtual ASX Small-Mid Cap Conference on 16-17 March, 2021.

The Noxopharm presentation will focus on the Company's goal of establishing Veyonda (NOX66) as a highly sought-after, next generation immuno-oncology drug, to be used to boost the anti-cancer effectiveness of most standard anti-cancer therapies including radiotherapy, chemotherapy and immune checkpoint inhibitors.

This distinctive broad use across the spectrum of cancer treatments is based on a unique action of restoring immune function to tumours in a process referred as converting tumours from 'COLD' to 'HOT', restoring the ability of the body's immune system to take advantage of the anti-cancer action of the standard treatments.

Dr Kelly will review the Company's progress in generating the underlying proof-of-concept data towards it goal of raising both the potential commercial value and international profile of Veyonda.

Attendance at the virtual conference is complimentary.
To register, please visit: ASX Small-Mid Cap conference

Dr Kelly's presentation titled, "*ASX Small-Mid Cap Conference Presentation March 2021*" is attached.

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome/septic shock.

Veyonda is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has three main drug actions – highly selective inhibition of sphingosine kinase, STING signaling and autophagy. Sphingosine kinase inhibition contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies and immune checkpoint inhibitors;

STING signaling inhibition provides an anti-inflammatory effect, contributing to an anti-cancer action, but also potentially blocking sepsis; autophagy inhibition is believed to augment the immunotherapy effect of radiotherapy, in particular the triggering of an abscopal response.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR), and wholly owns Pharmorage, a private drug development company focused on drug development in the areas of sepsis and autoimmunity.

To learn more visit: https://www.noxopharm.com/

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the Covid-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.


NOXOPHARM
Noxopharm Limited (ASX:NOX)
ASX SMALL-MID CAP CONFERENCE PRESENTATION
March 2021
Discover
Develop
Deliver
Dr Graham Kelly
CEO and Managing Director

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Medical advances have helped delay the progression of many forms of cancer. However, once an aggressive cancer becomes metastatic (with secondary tumours), current treatment options generally are very limited in their effectiveness

Our aim is simple. To boost the effectiveness of most current forms of cancer treatment, delivering long-term remission in most patients, by restoring the cancer-fighting capacity of the body's immune system

We believe that Veyonda® is about to achieve that goal and in so doing revolutionise the treatment of cancer

Veyonda® breakthrough COLD to HOT immunotherapy drug

Activates immune cells

Increases trafficking of activated immune cells



Source: Dana-Faber Cancer Institute

Blocks autophagy ⇩ abscopal responses

Inhibits inflammation

Converts **COLD** tumors to **HOT** tumors

Treatment options for metastatic cancer

NOXOPHARM

Used in most cancers

- Radiotherapy
- Chemotherapy



Limited to certain cancer types

- Immunotherapy
- Radiopharmaceuticals
- Targeted therapies

Proof-of-concept being sought by NOX in 3 different cancer treatments



DARRT

Veyonda® + Low Dose Radiotherapy

A revolutionary new treatment for solid cancer

DARRT Program

Veyonda® + Low-Dose Radiotherapy

- In metastatic cancer, radiotherapy (RT) generally applied to 1 or 2 individual tumours
- Mainly used for relief of symptoms (eg pain, loss of function)
- No meaningful effect on patient survival or disease progression expected with low-dose RT alone

DARRT Program

Direct and Abscopal Response to Radiotherapy

- Aim is to deliver a dose of radiation to a single tumour and to shrink or eradicate that tumour
- In the overwhelming majority of cases, the effect of the radiation is restricted to the irradiated tumour
- In extremely rare cases, tumours outside of the field of radiation also shrink. This is an immune response known as an ABSCOPAL RESPONSE



Shrinkage of irradiated tumour

Standard response



Partial abscopal response

Complete abscopal response

Very rare abscopal response

Aim of DARRT therapy is to convert an abscopal response from extremely rare to commonplace

DARRT Program

Low-dose radiotherapy

- ☛ to a single lesion
- ☛ external beam radiotherapy
- ☛ 8-30 Gy
- ☛ 1-10 fractionated doses
- ☛ single cycle of radiotherapy

Veyonda® (NOX66)

- ☛ 21-day cycle: daily dosing for 14 days (7 days rest)
- ☛ starting Day -1
- ☛ repeat monthly cycles (in DARRT-2) until disease progression

RATIONALE

- ☛ standard dose of radiation designed to kill cancer cells
- ☛ low dose of radiation designed to damage cancer cells to trigger an immune response
- ☛ Veyonda used to tip that immune response over into an ABSCOPAL RESPONSE

Features:

- Highly accessible. External radiotherapy readily available
- Cost-effective treatment
- Very well tolerated
- Potential for all solid cancer types

DARRT Program

DARRT-1 Phase 1 trial

26 men with end-stage prostate cancer
- had stopped responding to treatment
- had metastatic and progressive disease
- were considered to have limited life-spans
- were treated with Veyonda + low-dose RT

- **In 10/15* men, tumours stopped growing or reduced in size**
- **10/16** had meaningful pain reduction**
- **Treatment well tolerated**
- **Abscopal responses confirmed in 4 men#**

* 15 patients had measurable disease as per RECIST v1.1 at 24 weeks
** 16 patients were evaluable for pain assessments at 24 weeks

First known demonstration of abscopal responses in prostate cancer in more than isolated cases

DARRT-2 Study Design

- Phase 1b/2a study
- Differs from DARRT-1 in higher Veyonda dose and repeat cycles
- Multi-national
- Prostate, breast, lung cancers
- 100-150 patients
- Abscopal responses + range of other anti-tumour responses
- Commencing H2 2021

LuPIN

Veyonda® + ^{177}lutetium-PSMA-617

An exciting new treatment for prostate cancer

LuPIN Program



Lu-PSMA-617 is a radioactive drug injected IV and designed to deliver radiation to every prostate cancer cell throughout the body

Acquired by Novartis in 2018 for **US$6 billion**

Proposed new treatment for prostate cancer once the cancer has spread widely

But ……

1/3rd men have little or no response; response in responders not long-lasting

Aim ……

Use Veyonda to boost the effectiveness of the Novartis drug ➡ more men responding as well as achieving significantly longer survival times

Phase I/II study. St Vincent's Hospital Sydney. 56 men. End-stage cancer. No remaining standard treatments. Anticipated median survival approximately 4.5 months

LuPIN: Interim Data Reporting

American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021

ANSWER: Yes, the combination of Veyonda and Lu-PSMA-617 looks to be considerably more effective than Lu-PSMA-617 on its own (*based on published Phase 2 data*[1])

56 men

400 + 800 mg + 1200 mg Veyonda

Median Overall Survival:

19.7 months

a remarkable result for this late stage of the disease

Combination was well tolerated

Noxopharm believes this to be a potential major breakthrough in the treatment of Stage 4 prostate cancer

1. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.228

LuPIN: Interim Survival Data

Median overall survival = *time when half the patients have died and half still alive*

Three standard lines of drug therapy once prostate cancer becomes metastatic



Historical data[1] → ~ 4.5 months

^{177}Lu-PSMA-617 alone[2] → 13.3 months

^{177}Lu-PSMA-617 + Veyonda (56 patients)[3] → 19.7 months

1. Buonerba C, et al. (2014) Future Oncol 10:1353–60. 2. Hofman M, et al. (2018) Lancet Oncol 19, 825. 3. Noxopharm ASX announcement 15 Feb 2021

IONIC

Veyonda ® + nivolumab (Opdivo®)

Overcoming resistance to checkpoint inhibitors

IONIC Study

Phase I/II proof-of-concept study



SUMMARY

Both DARRT and LuPIN have provided clear evidence of proof-of-concept

DARRT: **Adding Veyonda** to a low dose of radiotherapy not expected to do anything more than shrink a single tumour, led in men with end-stage prostate cancer to:

- A halt to disease progression or better in 10/15 men
- Confirmed ABSCOPAL RESPONSES in 4 (25%) men, where few reports in prostate cancer exist

LuPIN: **Adding Veyonda** to Lu-PSMA-617 in men with end-stage prostate cancer:

- Resulted in a median overall survival of **19.7** m versus **13.3** m with the Novartis drug on its own

IONIC trial

Veyonda has first-in-class action in the lab in converting COLD tumours to HOT, an action considered vital in overcoming resistance to drugs such as Opdivo (Bristol Myers Squibb)

Veyonda is well tolerated as a combination treatment

Our commercial end-point for Veyonda

A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity

Programs focusing on immuno-oncology and cell therapy remain the most attractive targets for partnering

In 2020, 52 deals >US$1 billion were transacted, 31 of these were for immuno-oncology and cell therapy assets and platforms

Key metrics

as at 12 March 2021



News Flow (next 6 months)

- IONIC-1 and DARRT-2 start patient recruitment
- COVID-19 clinical trial completion
- Growing first-in-class drug pipeline
- Pharmorage (subsidiary) progressing novel drug development for sepsis and autoimmunity


NOXOPHARM
For further information
email: info@noxopharm.com
web: www.noxopharm.com
twitter: @noxopharm
Discover
Develop
Deliver